SCHEMBL199806

SCHEMBL199806

CC1CC2=CC(=O)CC[C@@H]2[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 1.00
SHBG P04278 7/20 0.69
SERPINA6 P08185 2/20 0.69
SLC22A1 O15245 1/20 0.69
ALDH1A1 P00352 1/20 0.69
THRB P10828 1/20 0.69
PGR P06401 5/20 0.55
NR3C2 P08235 2/20 0.55
CYP19A1 P11511 1/20 0.50
PDK1 Q15118 1/20 0.48
PDK2 Q15119 1/20 0.48
PDK3 Q15120 1/20 0.48
PDK4 Q16654 1/20 0.48
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25863609 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1
SCHEMBL1255845 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1
SCHEMBL29880093 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1
SCHEMBL5188310 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1
SCHEMBL24102494 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1
SCHEMBL14342101 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1
SCHEMBL24103284 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1
SCHEMBL5026430 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1
SCHEMBL24103286 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1
SCHEMBL223290 1.00 AR (1.00) ARSHBGSERPINA6SLC22A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 308 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9393218-B2 Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers EPINAMICS GMBH (DE) 2016-07-19 US claimed
US-20150366800-A1 ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION ALLERGAN, INC. 2015-12-24 US claimed
EP-2667877-A2 ANDROGEN COMPOSITION FOR TREATING AN OPHTHALMIC CONDITION Allergan, Inc. (US) 2013-12-04 EP claimed
CN-103415292-A Androgen compositions for the treatment of ophthalmic conditions ALLERGAN INC 2013-11-27 CN claimed
WO-2012103186-A2 ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION ALLERGAN, INC. (US) 2012-08-02 WO claimed
US-20120190661-A1 ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION ALLERGAN, INC. 2012-07-26 US claimed
EP-1962815-B1 USE OF FILM-FORMING HAIR-CARE POLYMERS FROM THE GROUP OF POLYURETHANES AND PHARMACEUTICAL PREPARATIONS AND PLASTERS CONTAINING SAID POLYMERS EPINAMICS GMBH (DE) 2010-08-11 EP claimed
US-20100112027-A1 Penis Enlargement ADAMS KENNETH W 2010-05-06 US claimed
CN-101346134-A Use of film-forming hair-care polymers from the group of polyurethanes and pharmaceutical preparations and plasters containing said polymers EPINAMICS GMBH (DE) 2009-01-14 CN claimed
EP-1962815-A1 USE OF FILM-FORMING HAIR-CARE POLYMERS FROM THE GROUP OF POLYURETHANES AND PHARMACEUTICAL PREPARATIONS AND PLASTERS CONTAINING SAID POLYMERS Epinamics GmbH (DE) 2008-09-03 EP claimed
US-20070248658-A1 Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers EPINAMICS GMBH (DE) 2007-10-25 US claimed
WO-2007077029-A1 USE OF FILM-FORMING HAIR-CARE POLYMERS FROM THE GROUP OF POLYURETHANES AND PHARMACEUTICAL PREPARATIONS AND PLASTERS CONTAINING SAID POLYMERS EPINAMICS GMBH (DE) 2007-07-12 WO claimed
EP-1800671-A1 Use of film-forming hair care polymers and pharmaceutical preparations and patches comprising such polymers Bayer Schering Pharma Aktiengesellschaft (DE) 2007-06-27 EP claimed
US-20060222708-A1 Wafer comprising steroid hormones BAYER INTELLECTUAL PROPERTY GMBH (DE) 2006-10-05 US claimed
US-20050065159-A1 Penis enlargement Dr. Kenneth Adams Medicine Professional Corporation (CA) 2005-03-24 US claimed
WO-2005011705-A1 ENHANCEMENT OF ERECTILE FUNCTION ADAMS KENNETH W (CA) 2005-02-10 WO claimed
WO-2004011029-A2 PHARMACEUTICAL COMPOSITIONS FOR PENIS ENLARGEMENT ADAMS KENNETH W (CA) 2004-02-05 WO claimed
EP-1343804-A1 14(15)-UNSATURATED 15- AND/OR 16- SUBSTITUTED ANDROGENS WITH MIXED ANDROGEN-PROGESTATIONAL PROFILE Akzo Nobel N.V. (NL) 2003-09-17 EP claimed
WO-2002048169-A1 14(15)-UNSATURATED 15- AND/OR 16- SUBSTITUTED ANDROGENS WITH MIXED ANDROGEN-PROGESTATIONAL PROFILE AKZO NOBEL N.V. (NL) 2002-06-20 WO claimed
US-11938105-B1 Methods and compositions for the treatment of cancer cachexia OHIO STATE INNOVATION FOUNDATION (US) 2024-03-26 US disclosed
US-11560406-B2 Anti-androgen peptides and uses thereof in cancer therapy CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-01-24 US disclosed
US-11529323-B2 Methods and compositions for the treatment of cancer cachexia OHIO STATE INNOVATION FOUNDATION (US) 2022-12-20 US disclosed
US-20220202829-A1 NON-IRRITATING TESTOSTERONE EMULSIONS ALLERGAN, INC. 2022-06-30 US disclosed
US-20220000830-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2022-01-06 US disclosed
US-11090283-B2 Solid forms of selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2021-08-17 US disclosed
US-20210113588-A1 NON-IRRITATING TESTOSTERONE EMULSIONS ALLERGAN INC (US) 2021-04-22 US disclosed
US-10905696-B2 Androgen composition for treating an ophthalmic condition ALLERGAN, INC. (US) 2021-02-02 US disclosed
EP-3388066-B1 ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION ALLERGAN INC (US) 2020-11-04 EP disclosed
US-10780098-B2 Non-irritating testosterone emulsions ALLERGAN, INC. (US) 2020-09-22 US disclosed
US-20200289438-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA OHIO STATE INNOVATION FOUNDATION 2020-09-17 US disclosed
EP-3681493-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA The Ohio State Innovation Foundation (US) 2020-07-22 EP disclosed
EP-3147278-B1 COMPOUND FOR TREATING BREAST CANCER AND PROGESTIN-DEPENDENT CONDITIONS UNIV TENNESSEE RES FOUND (US) 2020-02-12 EP disclosed
EP-2871177-B1 Solid form of (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide GTX INC (US) 2019-07-17 EP disclosed
WO-2019055687-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA OHIO STATE INNOVATION FOUNDATION (US) 2019-03-21 WO disclosed
EP-3412685-A1 ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY Cancer Research Technology Ltd. (GB) 2018-12-12 EP disclosed
EP-3388066-A1 ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION Allergan, Inc. (US) 2018-10-17 EP disclosed
US-20180271933-A1 ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY CANCER RESEARCH TECH LTD (GB) 2018-09-27 US disclosed
US-20180221388-A1 NON-IRRITATING TESTOSTERONE EMULSIONS ALLERGAN, INC. 2018-08-09 US disclosed
EP-2139917-B1 ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY CANCER RESEARCH TECH LTD (GB) 2018-04-25 EP disclosed
US-9937188-B2 Non-irritating testosterone emulsions ALLERGAN, INC. (US) 2018-04-10 US disclosed
US-9919023-B2 Anti-androgen peptides and uses thereof in cancer therapy CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-03-20 US disclosed
EP-2667877-B1 ANDROGEN COMPOSITION FOR TREATING AN OPHTHALMIC CONDITION ALLERGAN INC (US) 2018-03-07 EP disclosed
EP-2205552-B1 CRYSTALLINE POLYMORPH OF THE SELECTIVE ANDROGEN MODULATORS (R) OR (S)-N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-(4-CYANOPHENOXY)-2-HYDROXY-2-METHYLPROPANAMIDE GTX INC (US) 2018-02-28 EP disclosed
US-20170266149-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS GTX, INC. (US) 2017-09-21 US disclosed
EP-2289872-B1 Medical uses of a selective androgen receptor modulator UNIV TENNESSEE RES FOUND (US) 2017-08-02 EP disclosed
US-20170189412-A1 ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION ALLERGAN, INC. 2017-07-06 US disclosed
EP-3147278-A1 COMPOUND FOR TREATING BREAST CANCER AND PROGESTIN-DEPENDENT CONDITIONS University of Tennessee Research Foundation (US) 2017-03-29 EP disclosed
CN-103251579-B Substituted N-anilid and using method thereof 田纳西大学研究基金会 2016-12-28 CN disclosed
US-9504646-B2 Androgen composition for treating an opthalmic condition ALLERGAN, INC. (US) 2016-11-29 US disclosed
US-9493403-B2 Treating androgen decline in aging male (ADAM)-associated conditions with SARMs UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2016-11-15 US disclosed
EP-2038252-B1 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2016-11-02 EP disclosed
CN-103553966-B The solid forms of SARM GTX公司 2016-09-07 CN disclosed
EP-3056483-A1 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF University of Tennessee Research Foundation (US) 2016-08-17 EP disclosed
US-9393218-B2 Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers EPINAMICS GMBH (DE) 2016-07-19 US disclosed
US-20160128969-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS GTX INC (US) 2016-05-12 US disclosed
EP-2054049-B1 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2016-04-13 EP disclosed
US-9278914-B2 SARMs and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2016-03-08 US disclosed
US-20150366800-A1 ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION ALLERGAN, INC. 2015-12-24 US disclosed
CN-102976973-B SARM and using method thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2015-10-21 CN disclosed
US-9150501-B2 Solid forms of selective androgen receptor modulators GTX, INC. (US) 2015-10-06 US disclosed
US-9119772-B2 Androgen composition for treating an opthalmic condition ALLERGAN, INC. (US) 2015-09-01 US disclosed
US-20150202249-A1 ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-07-23 US disclosed
EP-2871177-A1 Solid form of (R) or (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide GTX, Inc. (US) 2015-05-13 EP disclosed
US-9011913-B2 Use of functionalized magnetic nanoparticles in cancer detection and treatment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-04-21 US disclosed
EP-2266577-B1 Multi-substituted selective androgen receptor modulators and methods of use therof UNIV TENNESSEE RES FOUNDATION (US) 2014-12-03 EP disclosed
CN-103073450-B Solid forms of selective androgen receptor modulators GTX CORP 2014-12-03 CN disclosed
US-20140315872-A1 NON-IRRITATING TESTOSTERONE EMULSIONS ALLERGAN, INC. (US) 2014-10-23 US disclosed
US-8846756-B2 Substituted acylanilides and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2014-09-30 US disclosed
US-20140221479-A1 SARMS AND METHOD OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2014-08-07 US disclosed
US-20140163115-A1 Migraine Treatments using the Bone Homeostasis Drug Cinacalcet ZAMOYSKI MARK (US) 2014-06-12 US disclosed
US-8669286-B2 SARMs and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2014-03-11 US disclosed
US-20140051764-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2014-02-20 US disclosed
CN-103553966-A Solid forms of selective androgen receptor modulators GTX INC 2014-02-05 CN disclosed
US-20140005263-A1 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2014-01-02 US disclosed
CN-101516840-B Substituted acylanilides and methods of use thereof UNIV TENNESSEE RES FOUNDATION 2013-12-25 CN disclosed
US-20130324602-A1 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2013-12-05 US disclosed
EP-2667877-A2 ANDROGEN COMPOSITION FOR TREATING AN OPHTHALMIC CONDITION Allergan, Inc. (US) 2013-12-04 EP disclosed
CN-103415292-A Androgen compositions for the treatment of ophthalmic conditions ALLERGAN INC 2013-11-27 CN disclosed
US-8563606-B2 Solid forms of selective androgen receptor modulators GTX, INC. (US) 2013-10-22 US disclosed
CN-103251579-A Substituted acylanilides and methods of use thereof UNIV TENNESSEE RES FOUNDATION 2013-08-21 CN disclosed
CN-101855198-B Solid forms of selective androgen receptor modulators UNIV TENNESSEE RES FOUNDATION 2013-07-10 CN disclosed
CN-101528214-B Substituted anilides and methods of use thereof UNIV TENNESSEE RES FOUNDATION 2013-06-05 CN disclosed
US-8445534-B2 Treating androgen decline in aging male (ADAM)-associated conditions with SARMs UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-05-21 US disclosed
US-20130122085-A1 PHARMACEUTICAL COMPOSITIONS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF GTX, INC. (US) 2013-05-16 US disclosed
WO-2013067170-A1 PHARMACEUTICAL COMPOSITIONS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF GTX, INC. (US) 2013-05-10 WO disclosed
CN-103073450-A Solid forms of selective androgen receptor modulators UNIV TENNESSEE RES FOUNDATION 2013-05-01 CN disclosed
EP-1592658-B1 Large-scale synthesis of selective androgen receptor modulators UNIV TENNESSEE RES FOUNDATION (US) 2013-04-24 EP disclosed
US-8426465-B2 Substituted acylanilides and methods of use thereof UNIVERSITY OF TENNESSE RESEARCH FOUNDATION (US) 2013-04-23 US disclosed
CN-102976973-A Selective androgen receptor modulator and method for using thereof UNIV TENNESSEE RES FOUNDATION 2013-03-20 CN disclosed
US-20130058946-A1 Seizure and Migraine Treatments using Denosumab ZAMOYSKI MARK JOHN (US) 2013-03-07 US disclosed
US-20130035387-A1 SARMS AND METHOD OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-02-07 US disclosed
CN-102905526-A SARM and methods of use thereof UNIV TENNESSEE RES FOUNDATION 2013-01-30 CN disclosed
US-8309603-B2 SARMs and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2012-11-13 US disclosed
US-20120214876-A1 Seizure and Migraine Treatments using the Bone Homeostasis Drug Cinacalcet ZAMOYSKI MARK JOHN (US) 2012-08-23 US disclosed
WO-2012103186-A2 ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION ALLERGAN, INC. (US) 2012-08-02 WO disclosed
US-20120190661-A1 ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION ALLERGAN, INC. 2012-07-26 US disclosed
US-8197858-B2 Use of calcitonin, SERMs such as raloxifene, testosterone, estrogen, calcimimetics such as cinacalcet, RANKL inhibitors such as denosumab, and bisphosphonates such as risedronate ZAMOYSKI MARK JOHN (US) 2012-06-12 US disclosed
US-20120136052-A1 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2012-05-31 US disclosed
EP-2457892-A1 Large-scale synthesis of selective androgen receptor modulators University of Tennessee Research Foundation (US) 2012-05-30 EP disclosed
CN-1726185-B Halogeno-selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION 2012-05-23 CN disclosed
CN-101284795-B Non-steroidal male hormone receptor regulating agent and medical uses thereof SHANGHAI INST MATERIA MEDICA 2012-04-25 CN disclosed
EP-1753417-B1 A SELECTIVE ANDROGEN RECEPTOR MODULATOR AND MEDICAL USES THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2012-04-04 EP disclosed
US-8110562-B2 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2012-02-07 US disclosed
US-8088828-B2 Treating benign prostate hyperplasia with SARMS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2012-01-03 US disclosed
US-8080682-B2 Substituted acylanilides and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2011-12-20 US disclosed
EP-1487458-B1 MULTI-SUBSTITUTED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2011-11-16 EP disclosed
US-20110263703-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-10-27 US disclosed
WO-2011132449-A1 ELECTRIC INCINERATOR TOILET, AND INCINERATION CONTROL METHOD FOR ELECTRIC INCINERATOR TOILET 株式会社ディラック (JP) 2011-10-27 WO disclosed
US-8003689-B2 Metabolites of selective androgen receptor modulators and methods of use thereof GTX, INC. (US) 2011-08-23 US disclosed
EP-1480634-B1 Selective androgen receptor modulators (SARMs) for treating benign prostate hyperplasia UNIV TENNESSEE RES FOUNDATION (US) 2011-08-03 EP disclosed
US-7977386-B2 Solid forms of selective androgen receptor modulators UNIVERSTIY OF TENNESSEE RESEARCH FOUNDATION (US) 2011-07-12 US disclosed
US-7968603-B2 Solid forms of selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2011-06-28 US disclosed
US-7968721-B2 Coupling a N-phenyl-1-bromo-2-substituted propamide with a substituted hydroxy-, amino-, phosphino-, or seleno- benzene compound; crystallization and filtration; industrial scale, high purity; non-steroidal agonists UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2011-06-28 US disclosed
CN-1700923-B Multi-substituted selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES CORP 2011-06-15 CN disclosed
US-20110082212-A1 MULTI-SUBSTITUTED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-04-07 US disclosed
EP-2305636-A1 Selective androgen receptor modulators and methods of use thereof University of Tennessee Research Foundation (US) 2011-04-06 EP disclosed
US-7919647-B2 N-(3-substituted-4-cyano)phenyl-2-hydroxy-2-methyl-3-(4-cyano)phenoxy propamides; spermatogenesis inhibitors, hormone replacement therapy, anticarcinogenic, antiproliferative agents for prostate cancer, apoptotic agents; bone and muscle disorders UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2011-04-05 US disclosed
US-20110077221-A1 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-03-31 US disclosed
EP-2289872-A2 Selective androgen receptor modulators and medical uses thereof University of Tennessee Research Foundation (US) 2011-03-02 EP disclosed
US-20110044911-A1 Use of Functionalized Magnetic Nanoparticles in Cancer Detection and Treatment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-02-24 US disclosed
EP-2284149-A1 Selective androgen receptor modulators and methods of use thereof University of Tennessee Research Foundation (US) 2011-02-16 EP disclosed
EP-2266577-A1 Multi-substitued selective androgen receptor modulators and methods of use therof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-12-29 EP disclosed
CN-1826313-B Large-scale synthesis of selective androgen receptor modulators GTX INC 2010-12-08 CN disclosed
US-20100280107-A1 TREATING BENIGN PROSTATE HYPERPLASIA WITH SARMS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2010-11-04 US disclosed
CN-101855198-A Solid forms of selective androgen receptor modulators UNIV TENNESSEE RES FOUNDATION 2010-10-06 CN disclosed
US-20100249228-A1 SARMS AND METHOD OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2010-09-30 US disclosed
US-7803970-B2 Multi-substitued selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-09-28 US disclosed
EP-2222636-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF Ligand Pharmaceuticals Inc. (US) 2010-09-01 EP disclosed
US-7776921-B2 Treating benign prostate hyperplasia with SARMS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-08-17 US disclosed
US-20100203168-A1 Bone microenvironment modulated seizure treatments ZAMOYSKI MARK JOHN 2010-08-12 US disclosed
WO-2009082437-A9 SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF LIGAND PHARMACEUTICALS INCORPORATED (US) 2010-08-12 WO disclosed
EP-1962815-B1 USE OF FILM-FORMING HAIR-CARE POLYMERS FROM THE GROUP OF POLYURETHANES AND PHARMACEUTICAL PREPARATIONS AND PLASTERS CONTAINING SAID POLYMERS EPINAMICS GMBH (DE) 2010-08-11 EP disclosed
US-7772433-B2 SARMS and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-08-10 US disclosed
US-20100189776-A1 ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY CANCER RESEARCH TECHNOLOGY LTD (GB) 2010-07-29 US disclosed
US-7759520-B2 Synthesis of selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-07-20 US disclosed
EP-2205552-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS University of Tennessee Research Foundation (US) 2010-07-14 EP disclosed
US-7741371-B2 Selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-06-22 US disclosed
US-20100137430-A1 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2010-06-03 US disclosed
CN-1736371-B Selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES CORP 2010-05-12 CN disclosed
US-20100112027-A1 Penis Enlargement ADAMS KENNETH W 2010-05-06 US disclosed
US-7705182-B2 preventing and/or treating dry eye conditions; cancer; hormone-related conditions; oral bioavailability, lack of cross-reactivity with other steroid receptors, and long biological half-lives UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-04-27 US disclosed
CN-101688248-A Androgen-dependent gene fusion comprising the 1f aromatase promoter and a reporter gene BAYER SCHERING PHARMA AG 2010-03-31 CN disclosed
US-7671091-B2 Penis enlargement Dr. Kenneth Adams Medicine Professional Corporation (CA) 2010-03-02 US disclosed
US-20100022641-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2010-01-28 US disclosed
US-7645898-B2 Selective androgen receptor modulators and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-01-12 US disclosed
US-20100004326-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF ONCTERNAL THERAPEUTICS, INC 2010-01-07 US disclosed
EP-2139917-A2 ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY Cancer Research Technology Ltd (GB) 2010-01-06 EP disclosed
WO-2009155481-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF GTX, INC. (US) 2009-12-23 WO disclosed
US-7622503-B2 Selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-11-24 US disclosed
US-20090264534-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2009-10-22 US disclosed
WO-2009123735-A1 USE OF FUNCTIONALIZED MAGNETIC NANOPARTICLES IN CANCER DETECTION AND TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-10-08 WO disclosed
CN-100537520-C N-bridged selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2009-09-09 CN disclosed
CN-101528214-A Substituted anilides and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2009-09-09 CN disclosed
CN-101516835-A Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof OSURF OHIO STATE UNIVERSITY RE (US) 2009-08-26 CN disclosed
CN-101516840-A Substituted acylanilides and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2009-08-26 CN disclosed
WO-2009082437-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-07-02 WO disclosed
US-20090156614-A1 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof OHIO STATE UNIVERSITY RESEARCH FOUNDATION 2009-06-18 US disclosed
EP-2054049-A2 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF University of Tennessee Research Foundation (US) 2009-05-06 EP disclosed
EP-1558565-B1 HALOGENATED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2009-04-29 EP disclosed
US-7518013-B2 Selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-04-14 US disclosed
US-20090088480-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2009-04-02 US disclosed
EP-2040709-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS, ANALOGS AND DERIVATIVES THEREOF AND USES THEREOF OSURF (US) 2009-04-01 EP disclosed
EP-2041077-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS, ANALOGS AND DERIVATIVES THEREOF AND USES THEREOF THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-04-01 EP disclosed
EP-2038252-A2 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF University of Tennessee Research Foundation (US) 2009-03-25 EP disclosed
WO-2009036206-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-03-19 WO disclosed
EP-1491524-B1 Selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2009-02-18 EP disclosed
CN-101346134-A Use of film-forming hair-care polymers from the group of polyurethanes and pharmaceutical preparations and plasters containing said polymers EPINAMICS GMBH (DE) 2009-01-14 CN disclosed
CN-101333174-A N-bridged selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2008-12-31 CN disclosed
US-20080319009-A1 Methylene-bridged selective androgen receptor modulators and methods of use thereof DALTON JAMES T 2008-12-25 US disclosed
EP-1562594-A4 METHYLENE-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2008-12-17 EP disclosed
CN-101284795-A Non-steroidal male hormone receptor regulating agent and medical uses thereof SHANGHAI INST MATERIA MEDICA (CN) 2008-10-15 CN disclosed
WO-2008113770-A2 ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY CANCER RESEARCH TECHNOLOGY LTD (GB) 2008-09-25 WO disclosed
EP-1962815-A1 USE OF FILM-FORMING HAIR-CARE POLYMERS FROM THE GROUP OF POLYURETHANES AND PHARMACEUTICAL PREPARATIONS AND PLASTERS CONTAINING SAID POLYMERS Epinamics GmbH (DE) 2008-09-03 EP disclosed
US-20080193380-A1 Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy DALTON JAMES T 2008-08-14 US disclosed
US-20080076829-A1 Substituted acylanilides and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2008-03-27 US disclosed
US-20080076828-A1 Substituted acylanilides and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2008-03-27 US disclosed
US-7344700-B2 Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 2008-03-18 US disclosed
US-20080057068-A1 SARMS and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2008-03-06 US disclosed
WO-2008024456-A2 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-02-28 WO disclosed
WO-2008011073-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS, ANALOGS AND DERIVATIVES THEREOF AND USES THEREOF OSURF (US) 2008-01-24 WO disclosed
WO-2008011072-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS, ANALOGS AND DERIVATIVES THEREOF AND USES THEREOF OSURF (OHIO STATE UNIVERSITY RESEARCH FOUNDATION) (US) 2008-01-24 WO disclosed
WO-2008008433-A2 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-01-17 WO disclosed
EP-1480634-A4 TREATING BENIGN PROSTATE HYPERPLASIA WITH SARMS GTX INC (US) 2008-01-16 EP disclosed
US-20070265290-A1 Heterocyclic selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2007-11-15 US disclosed
WO-2007126988-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-11-08 WO disclosed
CN-101062023-A Selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2007-10-31 CN disclosed
US-20070248658-A1 Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers EPINAMICS GMBH (DE) 2007-10-25 US disclosed
US-7253210-B2 Methylene-bridged selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-08-07 US disclosed
US-20070173546-A1 Selective androgen receptor modulators and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2007-07-26 US disclosed
WO-2007081696-A2 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS GTX, INC. (US) 2007-07-19 WO disclosed
CN-100999481-A Selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2007-07-18 CN disclosed
WO-2007077029-A1 USE OF FILM-FORMING HAIR-CARE POLYMERS FROM THE GROUP OF POLYURETHANES AND PHARMACEUTICAL PREPARATIONS AND PLASTERS CONTAINING SAID POLYMERS EPINAMICS GMBH (DE) 2007-07-12 WO disclosed
EP-1800671-A1 Use of film-forming hair care polymers and pharmaceutical preparations and patches comprising such polymers Bayer Schering Pharma Aktiengesellschaft (DE) 2007-06-27 EP disclosed
US-20070123563-A1 Selective androgen receptor modulators and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2007-05-31 US disclosed
CN-1972682-A Metabolites of selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2007-05-30 CN disclosed
CN-1964712-A Selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2007-05-16 CN disclosed
US-7214693-B2 Heterocyclic selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-05-08 US disclosed
US-7205437-B2 Selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-04-17 US disclosed
EP-1764357-A1 Selective androgen receptor modulators and methods of use thereof University of Tennessee Research Foundation (US) 2007-03-21 EP disclosed
US-20060287282-A1 Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof GTX, INC 2006-12-21 US disclosed
US-20060287547-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-12-21 US disclosed
US-20060276540-A1 Selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-12-07 US disclosed
US-20060276539-A1 Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS GTX, INC 2006-12-07 US disclosed
EP-1592658-A4 LARGE-SCALE SYNTHESIS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS GTX INC (US) 2006-11-29 EP disclosed
US-20060258628-A1 Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof GTX INC 2006-11-16 US disclosed
EP-1401801-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIV TENNESSEE RES CORP (US) 2006-11-02 EP disclosed
US-20060241180-A1 Selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSE RESEARCH FOUNDATION 2006-10-26 US disclosed
US-20060229362-A1 Selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-10-12 US disclosed
EP-1705174-A1 Selective androgen receptor modulators and methods of use thereof THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 2006-09-27 EP disclosed
EP-1487783-A4 IRREVERSIBLE SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2006-09-27 EP disclosed
EP-1534663-A4 N-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2006-08-30 EP disclosed
CN-1826313-A Large-scale synthesis of selective androgen receptor modulators GTX INC (US) 2006-08-30 CN disclosed
US-20060183931-A1 Multi-substituted selective androgen receptor modulators and methods of use thereof THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION 2006-08-17 US disclosed
EP-1487458-A4 MULTI-SUBSTITUED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2006-07-26 EP disclosed
CN-1771031-A Treating androgen deficiency in female (ADIF)-associated conditions with SARMS [ GTX INC (US) 2006-05-10 CN disclosed
EP-1558565-A4 HALOGENATED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2006-04-19 EP disclosed
US-7026500-B2 Halogenated selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2006-04-11 US disclosed
US-7022870-B2 N-bridged selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2006-04-04 US disclosed
EP-1594490-A4 TREATING ANDROGEN DEFICIENCY IN FEMALE (ADIF)-ASSOCIATED CONDITIONS WITH SARMS GTX INC (US) 2006-03-22 EP disclosed
CN-1736981-A Selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES CORP (US) 2006-02-22 CN disclosed
CN-1736371-A Selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES CORP (US) 2006-02-22 CN disclosed
US-20060035965-A1 Selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-02-16 US disclosed
US-20060035966-A1 Irreversible selective androgen receptor modulators and methods of use thereof DALTON JAMES T 2006-02-16 US disclosed
US-6998500-B2 Selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2006-02-14 US disclosed
US-6995284-B2 Synthesis of selective androgen receptor modulators THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2006-02-07 US disclosed
CN-1726193-A Heterocycle SARM and using method thereof UNIV TENNESSEE RES FOUNDATION (US) 2006-01-25 CN disclosed
CN-1726020-A Treatment of androgen decline in aging Male (ADAM) -associated diseases with SARM GTX INC (US) 2006-01-25 CN disclosed
CN-1726185-A Halogeno-selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2006-01-25 CN disclosed
CN-1726019-A Treating obesity with selective androgen receptor modulators GTX INC (US) 2006-01-25 CN disclosed
CN-1726034-A The SARM of methylene-bridged and application process thereof UNIV TENNESSEE RES FOUNDATION (US) 2006-01-25 CN disclosed
US-20060009529-A1 Synthesis of selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-01-12 US disclosed
US-20060004042-A1 Formulations comprising selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-01-05 US disclosed
CN-1230418-C Selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES CORP (US) 2005-12-07 CN disclosed
CN-1700923-A Multi-substituted selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES CORP (US) 2005-11-23 CN disclosed
EP-1487780-A4 HALOACETAMIDE AND AZIDE SUBSTITUTED COMPOUNDS AND METHODS OF USE THEREOF UNIV TENNESSEE RES FOUNDATION (US) 2005-11-16 EP disclosed
EP-1594490-A2 TREATING ANDROGEN DEFICIENCY IN FEMALE (ADIF)-ASSOCIATED CONDITIONS WITH SARMS GTX, Inc. (US) 2005-11-16 EP disclosed
EP-1592658-A2 LARGE-SCALE SYNTHESIS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS GTX Inc. (US) 2005-11-09 EP disclosed
CN-1694864-A N-bridged selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES FOUNDATION (US) 2005-11-09 CN disclosed
US-20050209320-A1 Anti-cancer compounds and methods of use thereof GTX, INC. 2005-09-22 US disclosed
EP-1562906-A2 HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF University of Tennessee Research Foundation (US) 2005-08-17 EP disclosed
EP-1562594-A2 METHYLENE-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF University of Tennessee Research Foundation (US) 2005-08-17 EP disclosed
EP-1558233-A2 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS GTX, Inc. (US) 2005-08-03 EP disclosed
EP-1558565-A2 HALOGENATED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2005-08-03 EP disclosed
CN-1646479-A Irreversible selective androgen receptor modulators and methods of use thereof UNIV TENNESSEE RES CORP (US) 2005-07-27 CN disclosed
CN-1639110-A Haloacetamide and azide substituted compounds and methods of use thereof UNIV TENNESSEE RES CORP (US) 2005-07-13 CN disclosed
EP-1534663-A1 N-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF University of Tennessee Research Foundation (US) 2005-06-01 EP disclosed
WO-2005037206-A2 ANTI-CANCER COMPOUNDS AND METHODS OF USE THEREOF GTX, INC. (US) 2005-04-28 WO disclosed
US-20050080054-A1 Treating androgen decline in aging male (ADAM)-associated conditions with SARMS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-04-14 US disclosed
US-20050065159-A1 Penis enlargement Dr. Kenneth Adams Medicine Professional Corporation (CA) 2005-03-24 US disclosed
US-20050038110-A1 N-phenyl-2-hydroxy-2-methyl-3-(p-cyano)phenoxypropamides; spermatogenesis inhibitors, hormone replacement therapy, anticarcinogenic agents for prostate cancer, apoptotic agents, dry eye UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-02-17 US disclosed
US-20050032750-A1 Treating androgen deficiency in female (ADIF)-associated conditions with SARMS GTX INC 2005-02-10 US disclosed
US-20050033074-A1 Multi-substitued selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-02-10 US disclosed
WO-2005011705-A1 ENHANCEMENT OF ERECTILE FUNCTION ADAMS KENNETH W (CA) 2005-02-10 WO disclosed
US-6838484-B2 Formulations comprising selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2005-01-04 US disclosed
US-20040265916-A1 Method for detecting selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2004-12-30 US disclosed
US-20040260092-A1 Large-scale synthesis of selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2004-12-23 US disclosed
US-20040260108-A1 Metabolites of selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2004-12-23 US disclosed
EP-1487783-A2 IRREVERSIBLE SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF University of Tennessee Research Foundation (US) 2004-12-22 EP disclosed
EP-1487780-A1 HALOACETAMIDE AND AZIDE SUBSTITUTED COMPOUNDS AND METHODS OF USE THEREOF THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 2004-12-22 EP disclosed
EP-1487458-A2 MULTI-SUBSTITUED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 2004-12-22 EP disclosed
EP-1480634-A2 TREATING BENIGN PROSTATE HYPERPLASIA WITH SARMS GTX, Inc. (US) 2004-12-01 EP disclosed
US-20040224979-A1 Treating obesity with selective androgen receptor modulators TENNESSEE RESEARCH FOUNDATION, UNIVERSITY OF 2004-11-11 US disclosed
EP-1470151-A1 PROCESS FOR THE PREPARATION OF 7-ALPHA-METHYLSTEROIDS Akzo Nobel N.V. (NL) 2004-10-27 EP disclosed
US-20040197928-A1 Method for detecting selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2004-10-07 US disclosed
US-20040167103-A1 Haloacetamide and azide substituted compounds and methods of use thereof TENNESSEE, UNIVERSITY OF RESEARCH FOUNDATION 2004-08-26 US disclosed
EP-1401801-A4 SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIV TENNESSEE RES CORP (US) 2004-08-18 EP disclosed
WO-2004064747-A2 TREATING ANDROGEN DEFICIENCY IN FEMALE (ADIF)-ASSOCIATED CONDITIONS WITH SARMS GTX INC. (US) 2004-08-05 WO disclosed
US-20040147489-A1 Haloacetamide and azide substituted compounds and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE 2004-07-29 US disclosed
US-20040147550-A1 Methylene-bridged selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2004-07-29 US disclosed
WO-2004062612-A2 LARGE-SCALE SYNTHESIS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS GTX INC. (US) 2004-07-29 WO disclosed
US-20040138244-A1 Heterocyclic selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2004-07-15 US disclosed
US-20040087810-A1 Irreversible selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE 2004-05-06 US disclosed
WO-2004035737-A2 HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2004-04-29 WO disclosed
WO-2004035739-A2 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS GTX, INC. (US) 2004-04-29 WO disclosed
WO-2004035736-A2 HALOGENATED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2004-04-29 WO disclosed
WO-2004035738-A2 METHYLENE-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2004-04-29 WO disclosed
US-20040067979-A1 N-bridged selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2004-04-08 US disclosed
EP-1401801-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 2004-03-31 EP disclosed
US-20040052727-A1 Radiolableled selective androgen receptor modulators andtheir use in prostate cancer imaging and therapy UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2004-03-18 US disclosed
US-20040053897-A1 Treating benign prostate hyperplasia with SARMS TENNESSEE RESEARCH FOUNDATION, UNIVERSITY OF 2004-03-18 US disclosed
US-20040029913-A1 Halogenated selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2004-02-12 US disclosed
WO-2004011029-A2 PHARMACEUTICAL COMPOSITIONS FOR PENIS ENLARGEMENT ADAMS KENNETH W (CA) 2004-02-05 WO disclosed
CN-1471508-A Selective androgen receptor modulators and methods of use thereof ��ѧ�о��� 2004-01-28 CN disclosed
US-20040014975-A1 Synthesis of selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE 2004-01-22 US disclosed
WO-2003106401-A1 N-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2003-12-24 WO disclosed
US-20030232792-A1 Selective androgen receptor modulators and methods of use thereof TENNESSEE RESEARCH CORPORATION, THE UNIVERSITY OF 2003-12-18 US disclosed
US-20030225040-A1 Selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2003-12-04 US disclosed
US-20030199514-A1 Methods for improving efficacy of treatment with growth hormone secretagogues FRYBURG DAVID A (US) 2003-10-23 US disclosed
EP-1353938-A1 ANDROGENIC 7-SUBSTITUTED 11-HALOGENATED STEROIDS Schering Aktiengesellschaft (DE) 2003-10-22 EP disclosed
WO-2003074449-A2 MULTI-SUBSTITUED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2003-09-12 WO disclosed
WO-2003074471-A1 HALOACETAMIDE AND AZIDE SUBSTITUTED COMPOUNDS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2003-09-12 WO disclosed
WO-2003074450-A2 RADIOLABELED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND THEIR USE IN PROSTATE CANCER IMAGING AND THERAPY THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 2003-09-12 WO disclosed
WO-2003074473-A2 IRREVERSIBLE SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2003-09-12 WO disclosed
US-20030162761-A1 Formulations comprising selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE 2003-08-28 US disclosed
WO-2003065992-A2 TREATING BENIGN PROSTATE HYPERPLASIA WITH SARMS GTX, INC. (US) 2003-08-14 WO disclosed
WO-2003059931-A1 PROCESS FOR THE PREPARATION OF 7α-METHYLSTEROIDS AKZO NOBEL N.V. (NL) 2003-07-24 WO disclosed
US-6569896-B2 Useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION 2003-05-27 US disclosed
US-20030022868-A1 Selective androgen receptor modulators and methods of use thereof THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION 2003-01-30 US disclosed
US-6492554-B2 SUBSTITUTED ALPHA-HYDROXYISOBUTYRANILIDES; SUPPRESSING SPERMATOGENESIS; HORMONE THERAPY THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION 2002-12-10 US disclosed
US-20020173495-A1 Selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2002-11-21 US disclosed
WO-2002059139-A1 ANDROGENIC 7-SUBSTITUTED 11-HALOGEN STEROIDS SCHERING AKTIENGESELLSCHAFT (DE) 2002-08-01 WO disclosed
US-20020099036-A1 Selective androgen receptor modulators and methods of use thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2002-07-25 US disclosed
US-20020099096-A1 Selective androgen receptor modulators and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE 2002-07-25 US disclosed
WO-2002016310-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 2002-02-28 WO disclosed
EP-1128810-A1 DRUG DELIVERY DEVICE, ESPECIALLY FOR THE DELIVERY OF ANDROGENS LEIRAS OY (FI) 2001-09-05 EP disclosed
US-6160011-A Non-steroidal agonist compounds and their use in male hormone therapy THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 2000-12-12 US disclosed
WO-2000028967-A1 DRUG DELIVERY DEVICE, ESPECIALLY FOR THE DELIVERY OF ANDROGENS LEIRAS OY (FI) 2000-05-25 WO disclosed
WO-1998053826-A1 NON-STEROIDAL AGONIST COMPOUNDS AND THEIR USE IN MALE HORMONE THERAPY THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1998-12-03 WO disclosed
WO-1998053826-A1 NON-STEROIDAL AGONIST COMPOUNDS AND THEIR USE IN MALE HORMONE THERAPY THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1998-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136052-A1 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF CPT1B, MTPN, MUSK AR 388/4885SHBG 1917/4885SERPINA6 4113/4885
US-20030022868-A1 Selective androgen receptor modulators and methods of use thereof AR, SHBG, GNRHR AR 1/4885SHBG 2/4885SERPINA6 553/4885
US-20160128969-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 AR 1/4885SHBG 6/4885SERPINA6 1233/4885
US-20140221479-A1 SARMS AND METHOD OF USE THEREOF CPT1B, FABP4, SARM1 AR 1933/4885SHBG 282/4885SERPINA6 953/4885
US-20030232792-A1 Selective androgen receptor modulators and methods of use thereof CYP19A1, AR, SHBG AR 2/4885SHBG 3/4885SERPINA6 961/4885
US-20060035965-A1 Selective androgen receptor modulators and methods of use thereof AR, ESRRA, SHBG AR 1/4885SHBG 3/4885SERPINA6 556/4885
US-20130035387-A1 SARMS AND METHOD OF USE THEREOF CPT1B, FABP4, SARM1 AR 1933/4885SHBG 282/4885SERPINA6 953/4885
US-20040067979-A1 N-bridged selective androgen receptor modulators and methods of use thereof CYP19A1, SHBG, FSHR AR 4/4885SHBG 2/4885SERPINA6 1317/4885
US-20030225040-A1 Selective androgen receptor modulators and methods of use thereof CYP19A1, SHBG, FSHR AR 4/4885SHBG 2/4885SERPINA6 719/4885
US-20030162761-A1 Formulations comprising selective androgen receptor modulators AR, CYP19A1, SHBG AR 1/4885SHBG 3/4885SERPINA6 1004/4885
US-20100004326-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF AR, SHBG, GPR119 AR 1/4885SHBG 2/4885SERPINA6 1118/4885
US-20090264534-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, CYP19A1, SHBG AR 1/4885SHBG 3/4885SERPINA6 943/4885
US-20110263703-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 AR 1/4885SHBG 6/4885SERPINA6 1204/4885
US-20020173495-A1 Selective androgen receptor modulators and methods of use thereof AR, SHBG, FSHR AR 1/4885SHBG 2/4885SERPINA6 667/4885
US-20040224979-A1 Treating obesity with selective androgen receptor modulators AR, ADIPOR2, ADIPOR1 AR 1/4885SHBG 13/4885SERPINA6 500/4885
US-20110077221-A1 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof AR, ESRRA, SHBG AR 1/4885SHBG 3/4885SERPINA6 512/4885
US-20070173546-A1 Selective androgen receptor modulators and method of use thereof AR, SHBG, ESRRA AR 1/4885SHBG 2/4885SERPINA6 567/4885
US-20080076829-A1 Substituted acylanilides and methods of use thereof CPT1B, MTPN, MUSK AR 388/4885SHBG 1917/4885SERPINA6 4113/4885
US-20100137430-A1 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS AR, SHBG, SARM1 AR 1/4885SHBG 2/4885SERPINA6 2337/4885
US-20080193380-A1 Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy AR, SHBG, GNRHR AR 1/4885SHBG 2/4885SERPINA6 349/4885
US-20060258628-A1 Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof CYP19A1, CYP17A1, SRD5A1 AR 5/4885SHBG 6/4885SERPINA6 1485/4885
US-20040260108-A1 Metabolites of selective androgen receptor modulators and methods of use thereof AR, CYP19A1, SHBG AR 1/4885SHBG 3/4885SERPINA6 1567/4885
US-20220000830-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 AR 1/4885SHBG 6/4885SERPINA6 1233/4885
US-20040260092-A1 Large-scale synthesis of selective androgen receptor modulators FSHR, AR, CYP19A1 AR 2/4885SHBG 4/4885SERPINA6 1884/4885
US-20130122085-A1 PHARMACEUTICAL COMPOSITIONS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF AR, SHBG, INSR AR 1/4885SHBG 2/4885SERPINA6 228/4885
US-20170266149-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 AR 1/4885SHBG 6/4885SERPINA6 1233/4885
US-20020099096-A1 Selective androgen receptor modulators and methods of use thereof AR, GNRHR, SHBG AR 1/4885SHBG 3/4885SERPINA6 249/4885
US-20030199514-A1 Methods for improving efficacy of treatment with growth hormone secretagogues GHSR, CYP21A2, GHRHR AR 88/4885SHBG 6/4885SERPINA6 316/4885
US-20060229362-A1 Selective androgen receptor modulators and methods of use thereof AR, NR5A1, FSHR AR 1/4885SHBG 6/4885SERPINA6 461/4885
US-20110044911-A1 Use of Functionalized Magnetic Nanoparticles in Cancer Detection and Treatment FOLR1, MKI67, CD47 AR 1704/4885SHBG 2070/4885SERPINA6 3529/4885
US-20080057068-A1 SARMS and method of use thereof SARM1, CKMT1A; CKMT1B, TNNI3 AR 577/4885SHBG 87/4885SERPINA6 2132/4885
US-20140005263-A1 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS AR, SHBG, SARM1 AR 1/4885SHBG 2/4885SERPINA6 2337/4885
US-20060276540-A1 Selective androgen receptor modulators AR, CYP19A1, SHBG AR 1/4885SHBG 3/4885SERPINA6 844/4885
US-20050080054-A1 Treating androgen decline in aging male (ADAM)-associated conditions with SARMS AR, CYP17A1, CYP19A1 AR 1/4885SHBG 5/4885SERPINA6 3201/4885
US-20140051764-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 AR 1/4885SHBG 6/4885SERPINA6 1233/4885
US-20100022641-A1 SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 AR 1/4885SHBG 6/4885SERPINA6 1233/4885
US-20040053897-A1 Treating benign prostate hyperplasia with SARMS AR, SRD5A1, SRD5A2 AR 1/4885SHBG 38/4885SERPINA6 2861/4885
US-20130324602-A1 SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF CPT1B, MTPN, MUSK AR 388/4885SHBG 1917/4885SERPINA6 4113/4885
US-20070265290-A1 Heterocyclic selective androgen receptor modulators and methods of use thereof CYP19A1, FSHR, AR AR 3/4885SHBG 4/4885SERPINA6 1747/4885
US-20200289438-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA HDAC5, HDAC1, HDAC7 AR 11/4885SHBG 38/4885SERPINA6 517/4885
US-20070123563-A1 Selective androgen receptor modulators and method of use thereof AR, SHBG, ESRRA AR 1/4885SHBG 2/4885SERPINA6 567/4885
US-20020099036-A1 Selective androgen receptor modulators and methods of use thereof AR, SHBG, FSHR AR 1/4885SHBG 2/4885SERPINA6 250/4885
US-20040147489-A1 Haloacetamide and azide substituted compounds and methods of use thereof AR, CYP19A1, SHBG AR 1/4885SHBG 3/4885SERPINA6 2240/4885
US-20110082212-A1 MULTI-SUBSTITUTED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF SHBG, FSHR, AR AR 3/4885SHBG 1/4885SERPINA6 684/4885
US-20050032750-A1 Treating androgen deficiency in female (ADIF)-associated conditions with SARMS AR, SHBG, CYP19A1 AR 1/4885SHBG 2/4885SERPINA6 2714/4885
US-11938105-B1 Methods and compositions for the treatment of cancer cachexia HDAC5, HDAC1, HDAC7 AR 11/4885SHBG 38/4885SERPINA6 517/4885
US-20060009529-A1 Synthesis of selective androgen receptor modulators AR, CYP19A1, SHBG AR 1/4885SHBG 3/4885SERPINA6 1137/4885
US-20100249228-A1 SARMS AND METHOD OF USE THEREOF CPT1B, FABP4, SARM1 AR 1933/4885SHBG 282/4885SERPINA6 953/4885
US-20060035966-A1 Irreversible selective androgen receptor modulators and methods of use thereof AR, SHBG, FSHR AR 1/4885SHBG 2/4885SERPINA6 1460/4885
US-20080076828-A1 Substituted acylanilides and methods of use thereof CPT1B, MTPN, MUSK AR 502/4885SHBG 1706/4885SERPINA6 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.